CSPC Pharmaceutical Group Limited (CSPCY)
OTCMKTS · Delayed Price · Currency is USD
4.810
-0.240 (-4.75%)
Aug 7, 2025, 3:17 PM EDT
CSPC Pharmaceutical Group Revenue
CSPC Pharmaceutical Group had revenue of 7.01B CNY in the quarter ending March 31, 2025, a decrease of -21.91%. This brings the company's revenue in the last twelve months to 27.04B, down -16.49% year-over-year. In the year 2024, CSPC Pharmaceutical Group had annual revenue of 29.01B, down -7.76%.
Revenue (ttm)
27.04B CNY
Revenue Growth
-16.49%
P/S Ratio
4.01
Revenue / Employee
1.26M CNY
Employees
21,400
Market Cap
14.94B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 29.01B | -2.44B | -7.76% |
| Dec 31, 2023 | 31.45B | 513.21M | 1.66% |
| Dec 31, 2022 | 30.94B | 3.07B | 11.02% |
| Dec 31, 2021 | 27.87B | 2.92B | 11.73% |
| Dec 31, 2020 | 24.94B | 2.84B | 12.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |
| BioStem Technologies | 332.45M |
CSPC Pharmaceutical Group News
- 6 weeks ago - Medtide Launches Hong Kong IPO to Boost Weight-loss Business - Benzinga
- 7 weeks ago - AstraZeneca Inks China AI Research Deal For Chronic Diseases - NDTV
- 7 weeks ago - AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion - Benzinga
- 2 months ago - AstraZeneca signs US$5 billion research deal with China’s CSPC - BNN Bloomberg
- 2 months ago - CSPC Pharma Pursues Licensing Deals After Lackluster Earnings - Benzinga
- 2 months ago - Chinese biotech’s mega drug-licensing deals with multinationals surge - South China Morning Post
- 10 months ago - CSPC Pharmaceutical Group Limited goes ex dividend tomorrow - Seeking Alpha
- 10 months ago - AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline - Benzinga